Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 1
2006 2
2008 6
2009 3
2010 2
2011 3
2016 2
2017 1
2018 1
2019 5
2020 2
2021 2
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
Schatz CA, Zitzmann-Kolbe S, Moen I, Klotz M, Nair S, Stargard S, Bjerke RM, Wickstrøm Biseth K, Feng YZ, Indrevoll B, Cruciani V, Karlsson J, Haendler B, Nielsen CH, Alfsen MZ, Hammer S, Hennekes H, Cuthbertson A, Hagemann UB, Larsen A. Schatz CA, et al. Among authors: cuthbertson a. Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746. Online ahead of print. Clin Cancer Res. 2024. PMID: 38593212
Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
Böhnke N, Indrevoll B, Hammer S, Papple A, Kristian A, Briem H, Celik A, Mumberg D, Cuthbertson A, Zitzmann-Kolbe S. Böhnke N, et al. Among authors: cuthbertson a. Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):669-680. doi: 10.1007/s00259-023-06474-z. Epub 2023 Oct 26. Eur J Nucl Med Mol Imaging. 2024. PMID: 37882848 Free PMC article.
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
Zitzmann-Kolbe S, Kristian A, Zopf D, Kamfenkel C, Politz O, Ellingsen C, Hilbig J, Juul MU, Fonslet J, Nielsen CH, Schatz CA, Bjerke RM, Cuthbertson AS, Mumberg D, Hagemann UB. Zitzmann-Kolbe S, et al. Among authors: cuthbertson as. Mol Cancer Ther. 2023 Sep 5;22(9):1073-1086. doi: 10.1158/1535-7163.MCT-22-0808. Mol Cancer Ther. 2023. PMID: 37365121 Free PMC article.
Targeted thorium-227 conjugates as treatment options in oncology.
Karlsson J, Schatz CA, Wengner AM, Hammer S, Scholz A, Cuthbertson A, Wagner V, Hennekes H, Jardine V, Hagemann UB. Karlsson J, et al. Among authors: cuthbertson a. Front Med (Lausanne). 2023 Jan 9;9:1071086. doi: 10.3389/fmed.2022.1071086. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36726355 Free PMC article. Review.
Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model.
Berg-Larsen A, Mobergslien A, Moen I, Petros G, Kristian A, Gunvaldsen KS, Cruciani V, Wickstroem K, Bjerke RM, Karlsson J, Cuthbertson A. Berg-Larsen A, et al. Among authors: cuthbertson a. Front Med (Lausanne). 2022 Nov 15;9:1033303. doi: 10.3389/fmed.2022.1033303. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36457578 Free PMC article.
89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice.
Broer LN, Knapen DG, Suurs FV, Moen I, Giesen D, Waaijer SJH, Indrevoll B, Ellingsen C, Kristian A, Cuthbertson AS, de Groot DA, Cole PE, de Vries EGE, Hagemann UB, Lub-de Hooge MN. Broer LN, et al. Among authors: cuthbertson as. J Nucl Med. 2022 Nov;63(11):1715-1721. doi: 10.2967/jnumed.121.263079. Epub 2022 Apr 14. J Nucl Med. 2022. PMID: 35422447 Free article.
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
Lejeune P, Cruciani V, Berg-Larsen A, Schlicker A, Mobergslien A, Bartnitzky L, Berndt S, Zitzmann-Kolbe S, Kamfenkel C, Stargard S, Hammer S, Jørgensen JS, Jackerott M, Nielsen CH, Schatz CA, Hennekes H, Karlsson J, Cuthbertson AS, Mumberg D, Hagemann UB. Lejeune P, et al. Among authors: cuthbertson as. J Immunother Cancer. 2021 Oct;9(10):e002387. doi: 10.1136/jitc-2021-002387. J Immunother Cancer. 2021. PMID: 34615703 Free PMC article.
In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab.
Roy J, Jagoda EM, Basuli F, Vasalatiy O, Phelps TE, Wong K, Ton AT, Hagemann UB, Cuthbertson AS, Cole PE, Hassan R, Choyke PL, Lin FI. Roy J, et al. Among authors: cuthbertson as. Cancer Biother Radiopharm. 2021 May;36(4):316-325. doi: 10.1089/cbr.2020.4492. Cancer Biother Radiopharm. 2021. PMID: 34014767 Free PMC article.
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB, Wickstroem K, Hammer S, Bjerke RM, Zitzmann-Kolbe S, Ryan OB, Karlsson J, Scholz A, Hennekes H, Mumberg D, Cuthbertson AS. Hagemann UB, et al. Among authors: cuthbertson as. Cancer Biother Radiopharm. 2020 Sep;35(7):497-510. doi: 10.1089/cbr.2020.3568. Epub 2020 Apr 7. Cancer Biother Radiopharm. 2020. PMID: 32255671 Free PMC article. Review.
37 results